Literature DB >> 10352189

Prognosis after a complete remission in adult patients with idiopathic membranous nephropathy.

B J Laluck1, D C Cattran.   

Abstract

This review of the long-term outcome after a complete remission of proteinuria includes 82 adult patients with biopsy-proven idiopathic membranous glomerulonephritis (IMGN), who represented 25% of the total cases (82 of 323 cases) of IMGN in our registry. Complete remission was defined as at least two consecutive follow-up evaluations showing proteinuria of 0.3 g/d or less of protein. Before remission, 70% of the patients had nephrotic-range proteinuria (61% at presentation, 9% during follow-up), and 30% were always subnephrotic (protein level < 3.5 g/d). Mean total observation time was 101 +/- 56 months, with a postremission period of 69 +/- 60 months. Seventy-one percent of the patients remained in remission and 29% relapsed. In the relapse group, 46% relapsed to nephrotic-range proteinuria and 54% relapsed to subnephrotic levels. The plasma creatinine level remained stable in 86% of the patients (71 of 82 patients) but became or remained elevated despite a period of complete remission in the remaining 14% (8 of 82 patients). No patient went on to end-stage renal disease. Seventy-seven percent of the patients had no specific treatment within 6 months of remission, whereas 23% had steroid therapy alone or in combination with an immunosuppressive agent. In a multivariate analysis, the factors that favored both remission and its durability were persistent lower levels of proteinuria and female sex. Complete remission indicates an excellent long-term prognosis in patients with IMGN, but relapses are common and, in a small percentage, chronic renal insufficiency occurs. Thus, our data suggest that even this group of patients should be monitored on a regular basis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10352189     DOI: 10.1016/S0272-6386(99)70138-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  16 in total

1.  Relapse and its remission in Japanese patients with idiopathic membranous nephropathy.

Authors:  Shinji Kitajima; Kengo Furuichi; Norihiko Sakai; Akihiro Sagara; Yasuyuki Shinozaki; Tadashi Toyama; Yasunori Iwata; Miho Shimizu; Hitoshi Yokoyama; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2014-06-24       Impact factor: 2.801

2.  Complete and Partial Remission as Surrogate End Points in Membranous Nephropathy.

Authors:  Aliza Thompson; Daniel C Cattran; Melanie Blank; Patrick H Nachman
Journal:  J Am Soc Nephrol       Date:  2015-06-15       Impact factor: 10.121

3.  Effect of steroid and cyclosporine in membranous nephropathy that is resistant to steroid and/or cytotoxic treatment.

Authors:  Melahat Coban; Remziye Nur Eke; Filiz Kizilates; Secil Ucar; Fatih Dede
Journal:  Int J Clin Exp Med       Date:  2014-01-15

4.  Substitution of Oral for Intravenous Cyclophosphamide in Membranous Nephropathy.

Authors:  Leonella Luzardo; Gabriela Ottati; Jimena Cabrera; Hernando Trujillo; Mariela Garau; Carlota González Bedat; Ruben Coitiño; María H Aunchayna; José Santiago; Graciela Baldovinos; Ricardo Silvariño; Alejandro Ferreiro; Francisco González-Martínez; Liliana Gadola; Oscar Noboa; Hena Caorsi
Journal:  Kidney360       Date:  2020-08-07

5.  Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.

Authors:  Ali AlSahow; Abdullah Al-Muhaiteeb; Hani Nawar; Bassam AlHelal; Anas AlYousef; Emad Abdallah; Ahmad AbuShall; Sameh Elmekawi; Basem Meshal; Ahmed AlQallaf; Heba AlRajab
Journal:  Med Princ Pract       Date:  2022-01-12       Impact factor: 2.132

6.  Membranous Nephropathy: Quantifying Remission Duration on Outcome.

Authors:  Daniel C Cattran; Esther D Kim; Heather Reich; Michelle Hladunewich; S Joseph Kim
Journal:  J Am Soc Nephrol       Date:  2016-10-18       Impact factor: 10.121

Review 7.  [Membranous glomerulonephritis].

Authors:  S Scheidat; R A K Stahl
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

8.  Tacrolimus versus cyclophosphamide for patients with idiopathic membranous nephropathy and treated with steroids: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Haiting Huang; Zhao Liang; Xintong Zheng; Qin Qing; Xiuri Du; Zhiming Tang; Meili Wei; Chen Wang; Qiuhong Zhong; Xu Lin
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606

9.  Idiopathic membranous nephropathy in children.

Authors:  Beom Hee Lee; Hee Yeon Cho; Hee Gyung Kang; Il Soo Ha; Hae Il Cheong; Kyung Chul Moon; In Seok Lim; Yong Choi
Journal:  Pediatr Nephrol       Date:  2006-09-02       Impact factor: 3.651

Review 10.  Membranous nephropathy in children: clinical presentation and therapeutic approach.

Authors:  Shina Menon; Rudolph P Valentini
Journal:  Pediatr Nephrol       Date:  2009-11-12       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.